758 results Get ready for more action! Dutch investment screening continues to evolve Dutch investment screening is rapidly expanding: since June, the proposal for a separate defence regime has been published and the intended expansion of the regime of the Vifo Act to include AI and biotech has been announced. Reason for a quick update! Mira Deweerdt Junior Associate Brussels Google Shopping: self-preferencing can be abusive The European Court of Justice has confirmed that Google abused its dominance by favouring its own shopping comparison service and demoting competing ones. However, not all favouritism is doomed. Court of Appeal overturns first instance judgment and establishes that several prestressing steel producers are liable for the potential loss alleged by Deutsche Bahn The Court of Appeal of 's-Hertogenbosch ruled that several producers of prestressing steel are jointly and severally liable for potential loss that Deutsche Bahn may have suffered as a result of an infringement of competition law rules. The EU Artificial Intelligence Act: our 16 key takeaways The AI Act is the first comprehensive AI regulation in the world. In this first episode of our Artificial Intelligence series, we have set out our initial key takeaways on the AI Act based on the text as currently approved by the Council of the EU. District Court ruled on the recognition of the res judicata effect of a Turkish judgment and dismissed an antitrust follow on damages claim regarding the cathode-ray tube markets The District Court of Oost-Brabant recognized the res judicata effect of a Turkish court of appeal judgment, in which the Turkish court had dismissed antitrust damages claims brought by Vestel against Philips, Samsung, LGE, Technicolor, TTD and TDP. Stibbe advises Goed A multidisciplinary Stibbe team advised Goed and its shareholders on its binding agreement with Mulitpharma relating to the sale of Goed’s pharmaceutical retail and wholesale business. The Commission’s ‘killer’ pharma campaign: reason to complain? The European Commission is on the prowl in the pharma sector. Recent cases on alleged disparagement and pipeline drugs-killings show that it is not afraid to show its teeth and, ultimately, bite. Digital antitrust conduct: too elusive to catch? The ink on the Digital Market Act has barely dried, but fast-evolving digital developments already have competition authorities calling for new tools. Is Big Tech not kept in check by the DMA, the antitrust rules and the EU Merger Regulation after all? The Foreign Subsidies Regulation’s initial focus on China Although the text of the Foreign Subsidies Regulation is not aimed at specific countries, the European Commission’s initial enforcement actions appear to be targeting Chinese subsidies. Third time lucky: Intel wins loyalty rebate battle at EU top court The European Court of Justice has upheld the annulment of Intel’s EUR 1.06 billion fine for abuse of dominance. The judgment provides guidance on how to assess the anti-competitiveness of loyalty rebates. If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug. Tekst & Commentaar Mededingingsrecht Roos Elemans en Jurriaan van Gent droegen bij aan de nieuwe uitgave van Tekst & Commentaar Mededingingsrecht. Mede dankzij deze bijdrage kunnen (mededingings-)juristen actief op het gebied van investeringstoetsingen nu gebruikmaken van dit naslagwerk. Van procederen kun je leren? Rechterlijke toetsing van concentratiezaken in Nederland Roos Elemans en Simone Evans staan in een artikel voor het Tijdschrift Mededingingsrecht in de Praktijk stil bij de vraag: wel of geen beroep instellen tegen een concentratiebesluit? Jan-Jaap Koningsveld strengthens TMT/IP practice Stibbe Amsterdam Stibbe Amsterdam is pleased to announce the expansion of its TMT/IP practice with the appointment of Jan-Jaap Koningsveld as counsel. Jan-Jaap Koningsveld Counsel Amsterdam De Europese Commissie, de Staat en de (inter)nationale rechter: een staatssteunrechtelijk 'Game of Thrones' of checks and balances? De staatssteunrechtelijke bevoegdhedenverdeling tussen de Europese Commissie, de Staat en de rechter houdt de gemoederen bezig. Een voorbeeld hiervan biedt de Micula rechtspraak over investeringsarbitrage. Deze blog bespreekt dergelijke zaken. Stibbe Amsterdam appoints three new partners We are pleased to announce that Stibbe Amsterdam has promoted Roos Elemans, Lotte Hover-Boon and Daisy Nijkamp to partner effective 1 January 2025. These appointments will further strengthen our EU and Competition Law, Tax and Litigation practices. Pagination Previous page Page 16 Current page 17 Page 18 Page 19 Next page
Get ready for more action! Dutch investment screening continues to evolve Dutch investment screening is rapidly expanding: since June, the proposal for a separate defence regime has been published and the intended expansion of the regime of the Vifo Act to include AI and biotech has been announced. Reason for a quick update!
Google Shopping: self-preferencing can be abusive The European Court of Justice has confirmed that Google abused its dominance by favouring its own shopping comparison service and demoting competing ones. However, not all favouritism is doomed.
Court of Appeal overturns first instance judgment and establishes that several prestressing steel producers are liable for the potential loss alleged by Deutsche Bahn The Court of Appeal of 's-Hertogenbosch ruled that several producers of prestressing steel are jointly and severally liable for potential loss that Deutsche Bahn may have suffered as a result of an infringement of competition law rules.
The EU Artificial Intelligence Act: our 16 key takeaways The AI Act is the first comprehensive AI regulation in the world. In this first episode of our Artificial Intelligence series, we have set out our initial key takeaways on the AI Act based on the text as currently approved by the Council of the EU.
District Court ruled on the recognition of the res judicata effect of a Turkish judgment and dismissed an antitrust follow on damages claim regarding the cathode-ray tube markets The District Court of Oost-Brabant recognized the res judicata effect of a Turkish court of appeal judgment, in which the Turkish court had dismissed antitrust damages claims brought by Vestel against Philips, Samsung, LGE, Technicolor, TTD and TDP.
Stibbe advises Goed A multidisciplinary Stibbe team advised Goed and its shareholders on its binding agreement with Mulitpharma relating to the sale of Goed’s pharmaceutical retail and wholesale business.
The Commission’s ‘killer’ pharma campaign: reason to complain? The European Commission is on the prowl in the pharma sector. Recent cases on alleged disparagement and pipeline drugs-killings show that it is not afraid to show its teeth and, ultimately, bite.
Digital antitrust conduct: too elusive to catch? The ink on the Digital Market Act has barely dried, but fast-evolving digital developments already have competition authorities calling for new tools. Is Big Tech not kept in check by the DMA, the antitrust rules and the EU Merger Regulation after all?
The Foreign Subsidies Regulation’s initial focus on China Although the text of the Foreign Subsidies Regulation is not aimed at specific countries, the European Commission’s initial enforcement actions appear to be targeting Chinese subsidies.
Third time lucky: Intel wins loyalty rebate battle at EU top court The European Court of Justice has upheld the annulment of Intel’s EUR 1.06 billion fine for abuse of dominance. The judgment provides guidance on how to assess the anti-competitiveness of loyalty rebates.
If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.
Tekst & Commentaar Mededingingsrecht Roos Elemans en Jurriaan van Gent droegen bij aan de nieuwe uitgave van Tekst & Commentaar Mededingingsrecht. Mede dankzij deze bijdrage kunnen (mededingings-)juristen actief op het gebied van investeringstoetsingen nu gebruikmaken van dit naslagwerk.
Van procederen kun je leren? Rechterlijke toetsing van concentratiezaken in Nederland Roos Elemans en Simone Evans staan in een artikel voor het Tijdschrift Mededingingsrecht in de Praktijk stil bij de vraag: wel of geen beroep instellen tegen een concentratiebesluit?
Jan-Jaap Koningsveld strengthens TMT/IP practice Stibbe Amsterdam Stibbe Amsterdam is pleased to announce the expansion of its TMT/IP practice with the appointment of Jan-Jaap Koningsveld as counsel.
De Europese Commissie, de Staat en de (inter)nationale rechter: een staatssteunrechtelijk 'Game of Thrones' of checks and balances? De staatssteunrechtelijke bevoegdhedenverdeling tussen de Europese Commissie, de Staat en de rechter houdt de gemoederen bezig. Een voorbeeld hiervan biedt de Micula rechtspraak over investeringsarbitrage. Deze blog bespreekt dergelijke zaken.
Stibbe Amsterdam appoints three new partners We are pleased to announce that Stibbe Amsterdam has promoted Roos Elemans, Lotte Hover-Boon and Daisy Nijkamp to partner effective 1 January 2025. These appointments will further strengthen our EU and Competition Law, Tax and Litigation practices.